“Our results add to other recent data that support extending the therapeutic window for IV thrombolysis in acute ischemic stroke patients if endovascular thrombectomy is not available or ...

Intra-arterial thrombolysis via urokinase following reperfusion by endovascular thrombectomy for stroke does not affect survival without disability.

The global neurovascular device market is poised for steady expansion, with market valuation expected to reach USD 3.0 billion in 2024, according to the latest report by Future Market Insights. The ...

Europe, with a global market share of 32.7% in 2022, followed North America in the adoption of ischemic stroke aspiration systems. Germany, with a strong manufacturing industry base, contributed to ...

The U.S. Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the ...

The following is a summary of “Endovascular Treatment of Stroke Due to Medium-Vessel Occlusion,” published in the February 2025 issue of New England Journal of Medicine by Goyal et al. Researchers ...

TNKase — tenecteplase — is the first FDA-approved stroke medicine in nearly 30 years, offering a faster, simpler five-second ...

Notably, off-label tenecteplase had already become the preferred thrombolytic for acute ischemic stroke before the expanded .

The global Thrombectomy Devices Market, valued at US$ 1.7 billion in 2022, is projected to advance at a compound annual ...

DelveInsight's Interventional Neuroradiology Market Insights report provides the current and forecast market analysis, individual leading interventional neuroradiology companies' market shares, ...

The approval is based on results of the AcT trial, where tenecteplase was comparable to alteplase for safety and efficacy.